Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Common Equity (2019 - 2025)

Historic Common Equity for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $2.5 million.

  • Vivos Therapeutics' Common Equity fell 6696.67% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 6696.67%. This contributed to the annual value of $8.0 million for FY2024, which is 183527.98% up from last year.
  • According to the latest figures from Q3 2025, Vivos Therapeutics' Common Equity is $2.5 million, which was down 6696.67% from $4.6 million recorded in Q2 2025.
  • Vivos Therapeutics' Common Equity's 5-year high stood at $36.5 million during Q2 2021, with a 5-year trough of $46000.0 in Q3 2023.
  • Its 5-year average for Common Equity is $10.7 million, with a median of $7.0 million in 2023.
  • As far as peak fluctuations go, Vivos Therapeutics' Common Equity tumbled by 9953.32% in 2023, and later skyrocketed by 1656304.35% in 2024.
  • Over the past 5 years, Vivos Therapeutics' Common Equity (Quarter) stood at $25.5 million in 2021, then plummeted by 81.2% to $4.8 million in 2022, then crashed by 91.44% to $411000.0 in 2023, then skyrocketed by 1835.28% to $8.0 million in 2024, then crashed by 68.17% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $4.6 million for Q2 2025, and $4.4 million during Q1 2025.